1 / 15

Emerging Market Environment in the Indian Pharmaceutical Industry after TRIPS

Emerging Market Environment in the Indian Pharmaceutical Industry after TRIPS. Sudip Chaudhuri Indian Institute of Management Calcutta Roundtable Symposium on: The Emerging Legal and Policy Landscape of Intellectual Property Protection for Pharmaceuticals in India 17 and 18 March, 2012

matsu
Télécharger la présentation

Emerging Market Environment in the Indian Pharmaceutical Industry after TRIPS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Emerging Market Environment in the Indian Pharmaceutical Industry after TRIPS Sudip Chaudhuri Indian Institute of Management Calcutta Roundtable Symposium on: The Emerging Legal and Policy Landscape of Intellectual Property Protection for Pharmaceuticals in India 17and 18 March, 2012 National Law University, Jodhpur

  2. Pharmaceutical Industry in India • Product patent regime: • Till 1972 • No product patent protection • 1972 to 1995 (2005) • Again product patent regime • Since 1995 (2005)

  3. Situation till 1972 • Litigation – patent infringement cases to prevent the Indian firms from manufacturing • Underdeveloped industry, import dependence • MNC domination • Monopoly and high prices

  4. Situation after product patent abolition • Rise and growth of the industry • Self sufficiency and export surplus • Competition and low prices • Indian domination • No litigation

  5. Post-TRIPS: Some implications • M&As and tie-ups and rising MNC share • Manufacturing • Imports • Exports • R&D • Market structure and prices

  6. Patent protected monopolies in anti-cancer drugs (December 2010)

  7. Cost of treatment (per person per year) • Dasatinib (anti cancer): • Price Rs 3905, 70 mg tablet • Cost of treatment Rs 2 million (100 mg daily) comparable to UK price of GBP 30,477 suggesting no differential pricing

  8. Exports • Spectacular rise in exports • But the prospect of huge gains in the patent expired markets in developed countries particularly in USA have not materialized • Significant price erosions • Value added markets increasingly difficult • Some companies which have aggressively pursued growth in foreign markets with high costs and stakes have not always succeeded

  9. R&D for new drugs • R&D activities have diversified • But Indian pharmaceutical firms are yet to prove their competence in innovating new products • No NCE has yet been developed for marketing – neglected diseases neglected • There have been several setbacks and the partnership model has not always worked properly • What Indian companies have really demonstrated is the ability to develop generics – an ability which they acquired and improved during the pre-TRIPS period.

  10. Policy focus • Initial optimism of Indian generic companies have not really materialized • Required space of operations of generic companies • Compulsory licensing • Interest in and importance of Section 3(d), patent pool etc should not divert attention from the fundamentally important task of having a user-friendly CL system • Limit data protection • Price control • South-south collaboration for innovation

  11. For comments sudip@iimcal.ac.in

More Related